Pre-earnings options volume in Acelyrin Inc is normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 7.3%, or 58c, after results are released. Median move over the past eight quarters is 8.2%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLRN:
- Acelyrin says Phase 2b/3 trial of izokibep met primary endpoint
- ACELYRIN Reports Positive Izokibep Trial Results, Transitions Services
- ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit – Improving Quality of Life for Patients
- ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
- Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo